Tag: LRRK2
DNA Sequencing Market to Surpass US$ 14,755.5 Million by 2030, Says Coherent Market Insights (CMI)
CMI Next-Gen DNA Sequencing Solutions: Empowering Precision Medicine & Genetic Research for Advancements in Healthcare & Biotechnology Burlingame, June 07, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, Global DNA Sequencing Market is estimated to be valued at US$ 6,802.2 million in 2023 and is expected to exhibit a CAGR…
DNA Sequencing Market to Surpass US$ 14,755.5 Million by
Burlingame, June 07, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, Global DNA Sequencing Market is estimated to be valued at US$ 6,802.2 million in 2023 and is expected to exhibit a CAGR of 11.7% during the forecast period (2023-2030). Analysts’ Views on Global DNA Sequencing Market: Rising demand for…
Superior Cognition in the Oldest-Old; Novel MS Pathway; What Links Amyloid and Tau?
Superior global cognition in the oldest-old was associated with resistance to neurodegenerative pathologies, autopsy data showed. (Journal of Alzheimer’s Disease) Brain network models showed that people with higher intelligence scores took more time to solve difficult problems, and that slower solvers had higher average functional connectivity. (Nature Communications) The novel…
Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease
Samantha B. Haeberlein, PhD Biogen and Denali have announced that they are discontinuing a portion of the clinical development program for BIIB122 (also known as DNL151), an investigational small molecule inhibitor of LRRK2 in development for the treatment of Parkinson disease (PD). As a result of this decision, the phase…
Parkinson’s cure ‘inevitable’ after biomarker breakthrough
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced what it says is the ‘most significant breakthrough yet’ in the search for a Parkinson’s biomarker: a biological test for Parkinson’s disease. The test demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement…
The IPDGC/GP2 Hackathon – an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data
GWAS-level and post-GWAS analyses GWAS of PD have nominated 90 independent risk signals in individuals of European ancestry, explaining ~16–36% of the heritable risk7, as well as two additional risk signals in Asian populations8. Typically, published GWAS are accompanied by various follow-up analyses, but performing these analyses is not always…
Identification of novel prognostic targets in coronary artery disease and related complications using bioinformatics and next generation sequencing data analysis
Abstract Coronary artery disease (CAD) is the most common cardiovascular disorder and the leading cause of heart-related deaths in world. Increasing molecular targets have been discovered for CAD and CAD – related complications prognosis and therapy. However, there is still an urgent need to identify novel biomarkers. Therefore, we evaluated…
New Stem Cell-Derived Neuron Datasets Available
15 Feb 2023 It’s time to add two new stem cell databases to the neurological disease research toolbox. For one, Clive Svendsen at Cedars-Sinai Medical Center, Los Angeles, and colleagues at Answer ALS led a team of scientists that created motor neurons from induced pluripotent stem cells derived from 92…
Immunofluorescence-based assay to assess LRRK2 recruitment by Rab29
Feb 01, 2023 DOI: dx.doi.org/10.17504/protocols.io.bp2l69r8klqe/v1 Protocol Citation: Francesca Tonelli 2023. Immunofluorescence-based assay to assess LRRK2 recruitment by Rab29. protocols.io dx.doi.org/10.17504/protocols.io.bp2l69r8klqe/v1 License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited…
2022, a Year in Review
15 Jan 2023 Part 1 of 2The year 2022 was a turning point in Alzheimer’s research. It began with the Aduhelm debacle fresh on people’s mind. It ended with reassurance that amyloid removal indeed helps people with the disease, when lecanemab’s Phase 3 data showed a slowing of cognitive decline….
Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential
Weisman, D. & McKeith, I. Dementia with Lewy Bodies. Semin. Neurol. 27, 042–047 (2007). Article Google Scholar Foguem, C. & Manckoundia, P. Lewy Body Disease: Clinical and Pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr. Neurol. Neurosci. Rep. 2018 18:5 18, 1–9 (2018). CAS Google Scholar …
Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122
Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up to 400 patients…
